Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
More Information Supplier PageSunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
More Information Supplier PageSunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
More Information Supplier PageSulindac(Clinoril) is a non-steroidal anti-inflammatory drug of the arylalkanoic acid class.
More Information Supplier PageStaurosporine is a natural product originally isolated in 1977 from the bacterium Streptomyces staurosporeus. The main biological activity of staurosporine is the inhibition of protein kinases through the prevention of ATP binding to the kinase. This is achieved through the stronger affinity of staurosporine to the ATP-binding site on the kinase.
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier PageSRT1720 is an inhibitor developed intended as a small-molecule activator of the sirtuin subtype SIRT1.
More Information Supplier Page
